01 6Takecab
02 2Takecab/Vocinti
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2019 Revenue in Millions : 647
2018 Revenue in Millions : 535
Growth (%) : 21
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2020 Revenue in Millions : 771
2019 Revenue in Millions : 660
Growth (%) : 17
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2021 Revenue in Millions : 837
2020 Revenue in Millions : 739
Growth (%) : 22
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2022 Revenue in Millions : 837
2021 Revenue in Millions : 837
Growth (%) : 0
Main Therapeutic Indication : Gastrointestinal Diseases
Currency : USD
2023 Revenue in Millions : 781
2022 Revenue in Millions : 837
Growth (%) : 6
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2016 Revenue in Millions : 276
2015 Revenue in Millions : 50
Growth (%) : 448
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2017 Revenue in Millions : 494
2016 Revenue in Millions : 295
Growth (%) : 68
Main Therapeutic Indication : Gastrointestinal Disorders
Currency : USD
2018 Revenue in Millions : 518
2017 Revenue in Millions : 464
Growth (%) : 12%
